Navigation Links
Accuri Cytometers Completes $13 Million Series C Financing
Date:7/8/2008

--New Funds will Support Expanded Commercialization of the Revolutionary

Accuri C6 Flow Cytometer(R) System--

ANN ARBOR, Mich., July 8 /PRNewswire/ -- Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the completion of a $13 million Series C financing led by Fidelity Biosciences and Flagship Ventures. Current investors including Baird Venture Partners and Arboretum Ventures also participated in the financing. Accuri will use the proceeds from the Series C financing primarily to expand its commercialization activities for the Accuri C6 Flow Cytometer(R) System. Bahaa Fam, Venture Partner, Fidelity Biosciences and Harry Wilcox, Partner, Flagship Ventures, will join the company's Board of Directors.

Explicitly designed for routine use by biomedical researchers in their own labs, Accuri's flow cytometer system is a full featured bench-top cell analysis system that provides capabilities similar to industry-leading flow cytometers in a more user-friendly format and at a fraction of the cost.

"This successful Series C financing led by Fidelity Biosciences and Flagship Ventures reflects the progress we have achieved in developing and commercializing our breakthrough flow cytometer system," said Jennifer Baird, CEO of Accuri. "Our strong initial acceptance in the marketplace is now ramping up and these new resources will enable us to further expand the reach of our marketing and sales efforts. We are pleased that our existing venture investors all participated in this round, and we look forward to the contributions of our new Board members."

Accuri created its revolutionary C6 system with input from hundreds of researchers who use flow cytometry, including many whose research has been fettered by resource constraints in their facilities. The company teamed with Menlo Innovations, which brought its unique, award-winning methods to the development of
'/>"/>

SOURCE Accuri Cytometers Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
2. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
3. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
4. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
5. Boston Scientific Completes Acquisition of CryoCor
6. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
7. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
8. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
9. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
10. China-Biotics, Inc. Completes Foundation for Its New Plant
11. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...hed the Sixth Milestone in its Ofatumumab ...N, Denmark, October 10 /- G...d the sixth milestone for,ofatumumab (HuMax-CD20(R...SmithKline (GSK). A milestone payment of approxima...) was triggered by the first patient,receiving tre...
(Date:10/10/2008)...Oct. 10 /Xinhua-- Beike,Biotechnology...bal leader in,stem cell research and treatment thr...as signed eight separate mutual cooperation agreem...anding stem cell research organizations.,As part o...em Cell Expert,Advisory Committee" and a separate ...
(Date:10/10/2008)...RNewswire/ -- Twenty of Britain,s most,innovative ...bit their,ideas at the fifth annual SETsquared Par...eld at One Great George Street, London, from 8am o...m of technology innovators,in electronics, informa...Six companies will give 10-minute presentations to...
(Date:10/10/2008)...Newswire/ -- Takeda Pharmaceutical Company,Limited...earch and,Development Center, Inc., a wholly owned...ation that the U.S. Food and Drug Administration (...e alogliptin New Drug Application,(NDA) by the Pre...r 27,2008., "In our most recent discussion with ...
Breaking Biology Technology:Genmab Reaches Milestone in Ofatumumab Collaboration 2Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 2Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 3Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 2Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 3FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2
... In the weeks since DEMO 2007, I,ve had the chanc...d cinema site, Jaman.com . Launched at the confer...to rent at no cost or buy at prices that average a...site directly, the core of the Jaman.com experienc...n that,s part media player, part purpose-built br...
... Wauwatosa, Wis. - Looking to raise more venture ... will be one of 30 firms presenting at the annual ...n Overland Park, Kan. , ,ZyStor, which also presen...tional $15 million or more in anticipation of Phas... 2008. , ,The company, located in the Technology ...
... In a recent column for the Wisconsin Technology...f the University of Wisconsin System fueling our...,There is no doubt that the UW System is one of th...however, the system must be willing to innovate an... was created in 1971. The UW System and the Board...
... Madison, Wis. - State Senator Robert Cowles ad...t he hopes the worst news about the state of Wisco...y trickled out in anticipation of the Legislative... his Senate colleague and a software executive, is... both agree on is that the audit on state IT proje...
Other Biology Technology:We're "Jaman": Purpose-driven browsers drive next wave of Web applications 2We're "Jaman": Purpose-driven browsers drive next wave of Web applications 3ZyStor seeks to raise $15M for clinical trials 2ZyStor seeks to raise $15M for clinical trials 3UW System must remove barriers to innovation 2UW System must remove barriers to innovation 3UW System must remove barriers to innovation 4Is the worst over for state technology failures? 2
(Date:10/10/2008)... a little gooey, but it,s not turning mums, brains... at The Australian National University. , The st...earch (CMHR) at ANU suggests that despite fears m...tive functions, there is no evidence to suggest th...t of Mental Health Week, which runs until tomorrow...
(Date:10/9/2008)...all/ -- Aware, Inc. (Nasdaq:,AWRE), a leading supp...re,has scheduled a conference call to discuss the... of 2008 on Thursday, October 23, 2008, at 5:00 p....Moberg will host the,earnings conference call., T...cessed on the,Investor Relations page of our websi...
(Date:10/9/2008)... Biology Laboratory (EMBL) have generated a digita...tal blueprint of a vertebrate. With a newly develo... track all cells for the first 24 hours in the lif...a three-dimensional, digital representation of the...e issue of Science , grants many new insights int...
(Date:10/9/2008)...nesian government and World Wildlife Fund (WWF) to...aining forests and critical ecosystems of Sumatra,...,s most diverse and endangered forests. The hist...de commitment to protect Sumatra,s stunning biodiv...vernors of all provinces across Sumatra, the world...
Breaking Biology News(10 mins):Pregnancy not turning minds to mush: Study 2Aware Announces Q3 2008 Earnings Conference Call 2Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate 2Saving Sumatra: Indonesia reaches historic agreement 2Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes Weekend Warriors 17462 1Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes Weekend Warriors 17462 2Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes Weekend Warriors 17462 3NIAID describes research priorities to fight drug resistant tuberculosis 17459 1NIAID describes research priorities to fight drug resistant tuberculosis 17459 2Ugandan monkeys harbor evidence of infection with unknown poxvirus 2996 1Ugandan monkeys harbor evidence of infection with unknown poxvirus 2996 2Ugandan monkeys harbor evidence of infection with unknown poxvirus 2996 3Clinton Centers Earth Day to Feature Innovate or Die Contest Winner 17455 1Clinton Centers Earth Day to Feature Innovate or Die Contest Winner 17455 2
...nsion, that is, blood pressure measuring above the...ed, it can lead to heart attacks, strokes, or kidn...treatment for the disease, but if they fail, medic...gh blood pressure have sought relief from compleme... many have consumed danshen, a Chinese herb used i...
...lished the first results showing that a biologica...effective gene therapy technique. Since then he h... the viruses that cause hepatitis and HIV in mice...under way - two in macular degeneration and one i... be among the first to find widespread use for tre...
...nvolves short DNA fragments (interfering RNA) that...on" into the corresponding, disease-related protei...rgeted delivery of RNA into the cells. Researchers...osen to use carbon nanotubes as their "means of tr... introduce RNA fragments that "switch off" the gen...
...atric specialists at Baylor College of Medicine ha...all nanoparticles as passkeys that allows drugs to... Jan. 21 issue of the journal Organic and Biomolec...elves by walling off the outside world. Cell walls...e cell,s inner machinery and its DNA blueprints. ...
Other Biology News:Active ingredient in common Chinese herb shown to reduce hypertension 2RNAi shows promise in gene therapy, Stanford researcher says 2Batten down the hatches against HIV 2Buckyballs used as 'passkey' into cancer cells 2
... is the first higher plant to be fully sequenced a...nism for gene expression research in higher plants...he ATH1 v.5 database of The Institute for Genomic ...base at the University of Delaware. Nearly 40,000 ...
... is in solution or in a gel piece, we can identify...s will be digested to produce a mixture of peptide...e determined by MALDI-TOF, and the amino acid sequ...F will be determined by MALDI-TOF/TOF. The masses ...
...interferons are cytopathic effect inhibition assay... types include; tissue culture supernatents; serum...ese assays, one unit is defined as the quantity of...cytopathic effect of viral infection by 50%. All...
supplied with 10x reaction buffer
Biology Products: